The Hong Kong University of Science and Technology

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Wing Yu Fu

Kit Yu Fu

Nancy Yuk-Yu Ip

Dimiter Stanchev Dimitrov

Tianlei Ying

Shuo Gu

Xuhui Huang

Fanny Chui-Fun Ip

Fanny Chui Fun Ip

Nancy Yuk Yu Ip

Guangmiao Fu

Kwok Wang Hung

Chui Fun Fanny Ip

Nancy Yuk-Yu Chu Ip

Fanny Chui Ip

Nancy Yuk Ip

New methods and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. The method includes administering to a subject in need thereof an effective amount of a small molecule compound inhibitor for EphA4 signaling. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

Heterocyclic compounds as EphA4 inhibitors

The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vector are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Human monoclonal antibodies against EphA4 and their use

The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Human monoclonal antibodies against EPHA4 and their use

Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root ofare structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.

CDK5 inhibitors and therapeutic uses thereof

Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving &#x3b2;-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

EphA4 inhibitors as neuroprotective agents

Growing community of inventors

Hong Kong, China

Wing Yu Fu